CanSino Biologics' (HKG:6185) subsidiary CanSino (Shanghai) Biological Research entered into a strategic cooperation framework agreement with deepGeneAI to jointly develop personalized mRNA therapeutic cancer vaccines.
The companies will explore combining CanSino's mRNA vaccine technology with deepGeneAI's tumor neoantigen discovery and design capabilities, according to a Wednesday Hong Kong bourse filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.